Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company") (NASDAQ:SLXP). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Salix concerning the Company's financial results, operations and business prospects. Salix is engaged in the acquisition, development and commercialization of prescription drugs and medical devices in the United States to treat gastrointestinal diseases.

The investigation relates to the Company's November 6, 2014, announcement of disappointing financial results for third quarter 2014, including a $88.6 million net loss, or $1.39 per diluted share, for the quarter and a downward revision of the Company's full-year revenue guidance. The Company further announced the abrupt resignation of its chief financial officer, and has named an interim CFO until a permanent successor is found. Following this news, Salix stock declined nearly 40% in after-hours trading on November 6, 2014.

If you purchased Salix shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to, or visit our website at

Copyright Business Wire 2010